Published in Physiol Res on January 01, 1999
[Intensive vitamin D supplementation in the treatment of osteoporosis]. Vnitr Lek (2004) 1.41
Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling. Methods Find Exp Clin Pharmacol (1995) 0.98
Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney Int Suppl (2001) 0.87
Advanced glycation end products and nutrition. Physiol Res (2002) 0.87
Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2-3. Physiol Res (2010) 0.84
Hippurate participates in the correction of metabolic acidosis. Kidney Int Suppl (2001) 0.82
Inhibitor(s) of protein synthesis in uremic serum and urine: partial purification and relationship to amino acid transport. Biochem Med (1982) 0.82
Acute effect of hydrochlorothiazide on renal calcium and magnesium handling in postmenopausal women. Physiol Res (1999) 0.82
Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol (1994) 0.82
The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron (1995) 0.82
Hippurate participation in the inhibition of glucose utilization in renal failure. Czech Med (1987) 0.81
Carbohydrate metabolism by rat liver slices incubated in serum obtained from uraemic patients. Clin Sci (1969) 0.81
Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin. J Cardiovasc Pharmacol (1985) 0.80
Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Physiol Res (1998) 0.80
Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers. Clin Chim Acta (2010) 0.80
Rooibos tea (Aspalathus linearis) partially prevents oxidative stress in streptozotocin-induced diabetic rats. Physiol Res (2005) 0.80
DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. Kidney Int Suppl (2001) 0.80
Serum hippurate and its excretion in conservatively treated and dialysed patients with chronic renal failure. Physiol Res (1991) 0.80
Analytical identity of an inhibitor of sodium transport isolated from human serum and urine. Nephron (1985) 0.80
Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population. Diabet Med (2013) 0.80
Plasma tryptophan level in chronic renal failure. Clin Nephrol (1980) 0.79
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens (2003) 0.79
Effect of hippurate on glucose utilization in rat kidney cortex slices. Ren Physiol Biochem (1991) 0.79
Gluconeogenesis in rat kidney after partial hepatectomy. Physiol Bohemoslov (1971) 0.79
Oxidative stress and plasma concentrations of coenzyme Q10, alpha-tocopherol, and beta-carotene in patients with a mild to moderate decrease of kidney function. Nephron (2001) 0.79
Does magnesium dysbalance participate in the development of insulin resistance in early stages of renal disease? Physiol Res (2002) 0.78
Advanced glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab (2000) 0.78
A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Methods Find Exp Clin Pharmacol (1996) 0.78
[Vitamin D: synthesis, metabolism, regulation, and an assessment of its deficiency in patients with chronic renal disease]. Vnitr Lek (2004) 0.77
Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: implications for renal failure. Nephron (1993) 0.77
Metabolic alterations caused by uraemia. Proc Eur Dial Transplant Assoc (1980) 0.77
Relation between the uptake of glucose and fatty acids by the rat kidney in vivo. Physiol Bohemoslov (1972) 0.77
The role of magnesium deficiency in insulin resistance: an in vitro study. J Hypertens Suppl (1991) 0.77
A procedure for the isolation of an inhibitor of sodium transport from the urine of uraemic patients. Physiol Bohemoslov (1982) 0.77
Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency. Adv Exp Med Biol (1987) 0.76
Pseudouridine excretion in healthy subjects and its accumulation in renal failure. Nephron (1992) 0.76
Magnesium deficiency impairs rat soleus muscle glucose utilization and insulin sensitivity. Mater Med Pol (1993) 0.76
High-glucose media enhance the responsiveness of tubular cells to growth promoters: effect on lysosomal cathepsins and protein degradation. Miner Electrolyte Metab (1998) 0.76
Fibrates and renal function. Clin Nephrol (2003) 0.76
Metabolism of palmitate-1-14C in the tissues of rats with streptozotocin diabetes. Physiol Bohemoslov (1981) 0.76
Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. Heart (2004) 0.75
[Effect of coenzyme Q10 in patients with kidney diseases]. Cas Lek Cesk (2001) 0.75
Accumulated end products participate in glucose intolerance and insulin resistance in uremia. Nephron (1993) 0.75
[Repeated administration of furosemide in intensive treatment of edema]. Vnitr Lek (1976) 0.75
[Uptake and utilization of palmitate 1 14C by some rat tissues in a medium of diabetic serum (author's transl)]. Cesk Gastroenterol Vyz (1978) 0.75
Abnormal carbohydrate metabolism in patients with liver cirrhosis; in vitro study. Diabetologia (1972) 0.75
[Prevention of chronic pyelonephritis relapses using metenamine hipuran (author's transl)]. Cas Lek Cesk (1979) 0.75
Abnormal carbohydrate metabolism in uraemia. Some properties of the inhibitor of glucose utilization present in the serum of uraemic patients. Int Urol Nephrol (1971) 0.75
[Choice of amoxycilin dosage in impaired renal function (author's transl)]. Bratisl Lek Listy (1978) 0.75
Ninhydrin-positive substances in serum and urine of patients with chronic uraemia. Clin Chim Acta (1972) 0.75
[Acute antihypertensive and diuretic effects of Metipamide VUFB]. Vnitr Lek (1985) 0.75
[Clinicopharmacologic aspects of the effects of serotonin and its blockade]. Bratisl Lek Listy (1985) 0.75
The synthesis of middle molecular substances in rat tissues: in vitro study. Proc Eur Dial Transplant Assoc (1978) 0.75
[Inhibition of red blood cell glucose utilization in uremia]. Vnitr Lek (1974) 0.75
Release of free fatty acids by the rat kidney. Physiol Bohemoslov (1977) 0.75
Pathophysiology of the carbohydrate metabolism in renal insufficiency. Rev Czech Med (1974) 0.75
Inhibition of glucose utilization in rat diaphragm by the urinary peptides fractionated by high-voltage electrophoresis. Int Urol Nephrol (1973) 0.75
[Short-term dialyses using a conventional hemodialyzer]. Z Urol Nephrol (1978) 0.75
Erythrocyte glycolysis in uraemia: cynamic balance caused by the opposite action of various factors. Int Urol Nephrol (1974) 0.75
[Metabolic changes in renal insufficiency]. Z Gesamte Inn Med (1978) 0.75
Carbohydrate metabolism in renal medullary slices. Physiol Bohemoslov (1967) 0.75
[Combination of methyldopa and diuretics in the treatment of hypertensive disease]. Vnitr Lek (1985) 0.75
[Metabolic changes in chronic kidney failure]. Bratisl Lek Listy (1978) 0.75
Blood level of middle molecular substances during uraemia and haemodialysis. Proc Eur Dial Transplant Assoc (1973) 0.75
[Treatment of oedematous conditions in combining amilorid and hydrochlorothiazid (author's transl)]. Bratisl Lek Listy (1976) 0.75
[Dihydralazin treatment of hypertension during hemodialysis]. Z Urol Nephrol (1973) 0.75
[Nephrotoxic effects of gentamicin in patients with damaged kidneys (author's transl)]. Bratisl Lek Listy (1979) 0.75
Acute effects of antagonist of S2-receptors. Czech Med (1984) 0.75
Pathogenesis of metabolic alterations in renal failure. Czech Med (1984) 0.75
[Ketanserin in the treatment of ischemic disease of the lower extremities]. Cas Lek Cesk (1985) 0.75
Localization of the inhibition of gluconegenesis in kidney slices by uremic serum. Med Exp Int J Exp Med (1968) 0.75
[How long and how often to dialyse patients with chronic renal failure (author's transl)]. Cas Lek Cesk (1977) 0.75
[Diuretic effects of chlorthalidone]. Vnitr Lek (1979) 0.75
[Uremia and glycide metabolism]. Cesk Fysiol (1973) 0.75
Plasma middle molecular substances (MMS) in schizophrenic patients. Int J Artif Organs (1979) 0.75
[Mean molecular substance volume in the sera of patients after kidney transplant operation (author's transl)]. Cas Lek Cesk (1977) 0.75
[Use of lactate in chronic uremia]. Vnitr Lek (1969) 0.75
[Clinical investigation of the sulfonamide diuretic, azosemide (BM 02 001)]. Vnitr Lek (1979) 0.75
[Effect of the inhibitor of glucose utilization, isolated from serum of patients in uremia, upon morphology and membrane permeability of erythrocytes (author's transl)]. Bratisl Lek Listy (1974) 0.75
Serum and ultradiafiltrate middle molecules in hemodialysed patients. Int Urol Nephrol (1979) 0.75